SNOA on Nasdaq

Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals, Inc. is an American surgical and medical instruments and apparatus company based in Dover.2 Its shares trade on Nasdaq under the symbol SNOA.2

$1.16 up 0.00 (0.00%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 20, 2026.

Overview

$19.5MRevenue, fiscal 20264
-$3.2MNet income, fiscal 20264

Compare with Spectral AI, Inc., NEPHROS INC or Vivos Therapeutics, Inc., or pick any stock.

  • TickerSNOA on Nasdaq2
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersDover, United States2
  • Incorporated inDE5
  • Business address5445 Conestoga Court, Suite 150, Boulder, Co 803015
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • Legal formCorporation2
  • LEI54930008C5Z4F02SWO712
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O COGENCY GLOBAL INC., 19904 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 42546742

See how the biggest companies compare on our leaderboards

Conestoga Court, Suite 150, Boulder, Colorado 80301. We have two active wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

38.0%Gross margin4
-12.6%Operating margin4
-16.3%Net margin4
36.7%Revenue growth, 20264
-102.6%Return on equity4
-$4.1MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue54¢$12.1M
  • Research and development10¢$2.3M
  • Selling, general and admin34¢$7.6M
  • Income tax1¢$244.0K

Out of $19.5M in revenue.4 The company lost money this year.

Financial statements

Revenue7891011124$19.5M in 2026+3% since 2019
0$5.0M$10.0M$15.0M$20.0M2019: $19.0M$19.0M20192020: $17.9M$17.9M2020−5%2021: $18.6M$18.6M2021+4%2022: $12.6M$12.6M2022−32%2023: $13.3M$13.3M2023+5%2024: $12.7M$12.7M2024−4%2025: $14.3M$14.3M2025+12%2026: $19.5M$19.5M2026+37%
Gross profit7891011124$7.4M in 2026−16% since 2019
0$2.5M$5.0M$7.5M$10.0M2019: $8.9M$8.9M20192020: $8.1M$8.1M2020−9%2021: $6.6M$6.6M2021−19%2022: $4.0M$4.0M2022−39%2023: $4.5M$4.5M2023+12%2024: $4.7M$4.7M2024+6%2025: $5.5M$5.5M2025+15%2026: $7.4M$7.4M2026+36%
Operating income7891011124-$2.5M in 2026−78% since 2019
-$15.0M-$10.0M-$5.0M02019: -$11.3M-$11.3M20192020: -$7.4M-$7.4M2020−34%2021: -$3.4M-$3.4M2021−53%2022: -$5.9M-$5.9M2022+71%2023: -$4.6M-$4.6M2023−22%2024: -$4.7M-$4.7M2024+3%2025: -$3.7M-$3.7M2025−21%2026: -$2.5M-$2.5M2026−34%
Net income7891011124-$3.2M in 2026−73% since 2019
-$15.0M-$10.0M-$5.0M02019: -$11.8M-$11.8M20192020: -$3.3M-$3.3M2020−72%2021: -$4.0M-$4.0M2021+19%2022: -$5.1M-$5.1M2022+29%2023: -$5.2M-$5.2M2023+1%2024: -$4.8M-$4.8M2024−6%2025: -$3.5M-$3.5M2025−29%2026: -$3.2M-$3.2M2026−8%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2026-03-312025-03-31
Revenues$19.5M$14.3M
Cost of revenues$12.1M$8.8M
Gross profit$7.4M$5.5M
Research and development$2.3M$1.8M
Selling, general and administrative$7.6M$7.4M
Total operating expenses$9.9M$9.2M
Loss from operations-$2.5M-$3.7M
Other (expense) income-$958.0K$803.0K
Loss from operations before income taxes-$3.4M-$2.9M
Income tax benefit (expense)$244.0K-$550.0K
Net loss-$3.2M-$3.5M
Net loss per share: basic-$1.89-$2.79
Net loss per share: diluted-$1.89-$2.79
Weighted-average shares outstanding: basic1.7M shares1.2M shares
Weighted-average shares outstanding: diluted1.7M shares1.2M shares
Foreign currency translation adjustments$1.1M-$1.7M
Comprehensive loss-$2.0M-$5.1M

Compare Sonoma Pharmaceuticals, Inc. with another company

What it owns

What Sonoma Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$1.8M4 Mar 31, 2026$1.5M4 Mar 31, 2025+22.4%
Furniture and fixtures$134.0K4 Mar 31, 2026$121.0K4 Mar 31, 2025+10.7%
Leasehold improvements$556.0K4 Mar 31, 2026$491.0K4 Mar 31, 2025+13.2%
Property and equipment, before depreciation$2.8M4 Mar 31, 2026$2.3M4 Mar 31, 2025+21.3%
Accumulated depreciation$2.5M4 Mar 31, 2026$2.1M4 Mar 31, 2025+19.5%
Property and equipment, net$310.0K4 Mar 31, 2026$225.0K4 Mar 31, 2025+37.8%
Operating-lease assets (leased space)$602.0K4 Mar 31, 2026$84.0K4 Mar 31, 2025+616.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2.4M4 Mar 31, 2026$5.4M4 Mar 31, 2025−55.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$3.7M4 Mar 31, 2026$2.9M4 Mar 31, 2025+25.2%
Raw materials$2.1M4 Mar 31, 2026$1.4M4 Mar 31, 2025+49.3%
Finished goods$2.2M4 Mar 31, 2026$1.8M4 Mar 31, 2025+20.0%

Properties, in its own words

At March 31, 2026, we have a corporate office in Boulder, Colorado and our manufacturing facility in Zapopan, Mexico. We currently lease the following material properties:

Locations · Rent per month · Purpose

The rest of Item 2

1) 5445 Conestoga Court, Unit 150, Boulder, CO 80301 · USD 3,688 · Principal executive office

2) Industria Vidriera 81, & 87 Zapopan Industrial Norte, Zapopan, Jalisco, 45135, Mexico · MXN 209,811 · Office, manufacturing

3) Industria Maderera 106, 115 & 815 Zapopan Industrial Norte, Zapopan, Jalisco, 45135, Mexico · MXN 213,625 · Office, warehouse

We believe that our properties will be adequate to meet our needs for at least the next 12 months.

Item 2 of the 10-K filed Jun 16, 2026.6

Leadership

Who has led Sonoma Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Hojabr Alimi2007–2012
  2. James J. Schutz2013–2018
  3. Frederick J. Sandford2018–2019
  4. Amy Moss Trombly2019–now

President

  1. Hojabr Alimi2007

Chief financial officer

  1. Frederick J. Sandford2018–2019
  2. Poggetto John Dal2019–2020
  3. Jerome J. Dvonch2020–2022
  4. Chad Norman White2022

Chief operating officer

  1. Michael Wokasch2007
  2. James J. Schutz2009–2012
  3. Bruce Thornton2021–now
2010201520202025
Board members and other officers (20)

Former names

  • Oculus Innovative Sciences, Inc.Jan 15, 2002 to Dec 2, 20165

Timeline

  1. Oct 6, 20268-K Entered a material agreement; Change to shareholders' rights; Bylaws or fiscal year changed44
  2. Sep 17, 20268-K Shareholder vote45
  3. Aug 19, 20268-K Shareholder vote46
  4. Jun 18, 20268-K Other events47
  5. Apr 30, 20268-K Entered a material agreement; Other events48
  6. Apr 9, 20268-K Entered a material agreement49
  7. Jan 28, 20268-K Executive or director change50
  8. Jan 12, 20268-K Other events51
  9. Jan 2, 20268-K Executive or director change52
  10. Oct 23, 20258-K Executive or director change53
  11. Oct 9, 20258-K Executive or director change54
  12. Sep 29, 20258-K Other events55
  13. Oct 17, 2019New chief executive Amy Moss Trombly becomes CEO16
  14. Dec 21, 2018New chief executive Frederick J. Sandford becomes CEO17
  15. Aug 19, 2013New chief executive James J. Schutz becomes CEO18
  16. Jan 24, 2007New chief executive Hojabr Alimi becomes CEO19
  17. Nov 20, 2006Founded Sonoma Pharmaceuticals, Inc. is founded2

Calendar

Coming up

  1. Nov 3, 2026Reports results for the quarter ending Sep/202656

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

178 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 52 major events, 49 insider forms, 57 other. The latest 20:

  1. Oct 6, 20268-A12B/A AMENDMENT TO FORM 8-A12B EDGAR
  2. Oct 6, 20268-K CURRENT REPORT EDGAR
  3. Sep 17, 20268-K CURRENT REPORT EDGAR
  4. Aug 19, 20268-K EDGAR
  5. Aug 6, 202610-Q FORM 10-Q FOR JUN 2026 EDGAR
  6. Jul 28, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
  7. Jul 23, 2026DEFA14A NOTICE OF ADJOURNMENT EDGAR
  8. Jul 9, 20264 EDGAR
  9. Jul 9, 20264 EDGAR
  10. Jul 9, 20264 EDGAR
  11. Jul 9, 20264 EDGAR
  12. Jul 9, 20264 EDGAR
  13. Jul 9, 20264 EDGAR
  14. Jul 9, 2026S-8 EDGAR
  15. Jun 24, 2026DEFA14A EDGAR
  16. Jun 18, 20268-K CURRENT REPORT EDGAR
  17. Jun 18, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  18. Jun 16, 202610-K FORM 10-K FOR MAR 2026 EDGAR
  19. May 5, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
  20. Apr 30, 20268-K CURRENT REPORT EDGAR

The 178 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2026Amy TromblyChief Executive Officer$407.5K$741.1K57
2026Jerry DvonchChief Financial Officer$240.0K$422.7K57
2026Bruce ThorntonFormer Executive Vice President and Chief Operating Officer$170.5K$399.6K57
2025Amy TromblyChief Executive Officer$325.0K$597.1K57
2025Bruce ThorntonFormer Executive Vice President and Chief Operating Officer$260.8K$532.4K57
2025Jerry DvonchChief Financial Officer$240.0K$357.5K57

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Renaissance Technologies LLC40,468$49.8K0.0%New
Geode Capital Management, LLC26,787$32.9K0.0%+6,846
Vanguard Capital Management LLC18,787$23.1K0.0%No change
McKinley Carter Wealth Services, Inc.11,193$13.8K0.0%No change
UBS Group AG7,808$9.6K0.0%+7,802
Global Retirement Partners, LLC2,548$3.1K0.0%New
Morgan Stanley2,000$2.5K0.0%−4
Osaic Holdings, Inc.500$6150.0%No change
Barclays PLC459$5650.0%New
BlackRock, Inc.113$1390.0%No change
Vanguard Fiduciary Trust Co100$1230.0%No change
Harbour Investments, Inc.15$180.0%New
Quaker Wealth Management, LLC3$40.0%No change
Danske Bank A/s1$10.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Sonoma Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSonoma Pharmaceuticals, Inc.1
  • CIK0001367083
  • Employer ID (EIN)68-04232986
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company6
  • Incorporated inDelaware6
  • Fiscal year endsMarch 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address5445 Conestoga Court, Suite 150, Boulder, CO 803011
  • Phone800-759-93051
  • Shares outstanding4,788,425 as of Aug 6, 202615
  • Public float$6.3M as of Sep 30, 20256
  • AuditorFrazier & Deeter, LLC, Nashville, Tennessee PCAOB ID 215; no auditor attestation of internal control over financial reporting6
  • On EDGAR sinceJan 15, 20021
  • Filings977 in all: 4 (285), 8-K (217), 10-Q (59), CORRESP (41), 424B5 (35), 3 (31), UPLOAD (28), 424B3 (27)1
    All 45 form types

    DEF 14A (25), 10-K (20), S-1/A (20), DEFA14A (17), EFFECT (17), S-8 (16), CT ORDER (15), REGDEX (14), PRE 14A (9), S-1 (8), SC 13G (8), SC 13G/A (8), S-3 (7), POS AM (6), S-3/A (6), 10-Q/A (5), 8-K/A (5), 144 (4), 424B2 (4), FWP (4), NT 10-Q (4), REGDEX/A (4), SC 13D (4), 424B4 (3), 8-A12B (3), NT 10-K (3), 144/A (2), ARS (2), CERTNAS (2), SC 13D/A (2), 10-K/A (1), 25-NSE (1), 4/A (1), 8-A12B/A (1), AW (1), DRS (1), S-1MEF (1)

  • Latest filingsAnnual report (10-K) Jun 16, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Jul 28, 2026
    Latest 8-K (8-K) Oct 6, 2026

Risk factors and legal proceedings

The risks Sonoma Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Jun 16, 2026: 34 risks under these headings, as written.6

  • Risks Related to Our Business
  • We depend on third party distributors and intend to continue to license or collaborate with third parties in various potential markets, and events involving these strategic partners or any future collaboration could delay or prevent us from developing or commercializing products.
  • Mexican tax law prevents us from deducting intercompany interest expense incurred by our Mexico subsidiary Oculus Technologies of Mexico, S.A. de C.V and requires withholding tax on payments remitted to the US. At the same time, we are unable to recognize tax benefits for foreign tax credits for U.S. tax purposes.
  • We rely on a number of key customers who may not consistently purchase our products in the future, and if we lose any one of these customers, our revenues may decline.
  • A majority of our business is conducted outside of the United States, exposing us to additional risks that may not exist in the United States, which in turn could cause our business and operating results to suffer.
  • If we fail to obtain, or experience significant delays in obtaining, additional regulatory clearances or approvals to market our current or future products, we may be unable to commercialize these products.
  • If we fail to comply with ongoing regulatory requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.
  • If we fail to comply with ongoing regulatory requirements for our European products under the new Medical Devices Regulation, these products could be subject to withdrawal from the market.
  • If any of our third-party contractors fail to perform their responsibilities to comply with FDA rules and regulations, the manufacture, marketing and sales of our products could be delayed, which could decrease our revenues.
  • If we fail to comply with the FDA’s rules and regulations and are subject to an FDA recall as part of an FDA enforcement action, the associated costs could have a material adverse effect on our business, financial position, results of operations and cash flows.
  • Quality issues, concerns about safety or efficacy of our products, or failure to comply with governmental regulations could result in recall of our products and we could suffer adverse public relations that could adversely impact our sales, operating results, reputation and business operations.
  • If our products do not gain market acceptance, our business will suffer because we might not be able to fund future operations.
The other 23 risks
  • If our competitors develop products with similar characteristics to our HOCl technology, we may need to modify or alter our business strategy, which may delay the achievement of our goals.
  • Negative economic conditions increase the risk that we could suffer unrecoverable losses on our customers’ accounts receivable which would adversely affect our financial results.
  • We may experience difficulties in manufacturing our products, which could prevent us from commercializing one or more of our products.
  • Our competitive position depends on our ability to protect our intellectual property and our proprietary technologies.
  • We may face intellectual property infringement claims that could be time-consuming, costly to defend and could result in our loss of significant rights and, in the case of patent infringement claims, the assessment of treble damages.
  • We could be required to indemnify third parties for alleged intellectual property infringement, which could cause us to incur significant costs.
  • Our international operations are subject to trade policies, tariffs and trade agreements, and recent and future changes could harm our business.
  • Our sales in international markets subject us to foreign currency exchange and other risks and costs which could harm our business.
  • The markets in which we operate are highly competitive and subject to rapid technological change. If our competitors are better able to develop and market products that are less expensive or more effective than any products that we may develop, our commercial opportunity may be reduced or eliminated.
  • The success of our research and development efforts may depend on our ability to find suitable collaborators to fully exploit our capabilities. If we are unable to establish collaborations or if these future collaborations are unsuccessful, our research and development efforts may be unsuccessful, which could adversely affect our results of operations and financial condition.
  • If we are unable to comply with broad and complex federal and state fraud and abuse laws, including state and federal anti-kickback laws, we could face substantial penalties and our products could be excluded from government healthcare programs.
  • We may not be able to maintain sufficient product liability insurance to cover claims against us.
  • Our ability to generate revenue will be diminished if our partners are unable to obtain acceptable prices or an adequate level of reimbursement from third-party payors, or our partners may face pricing pressure from private third-party payers, including customers, from rebates and restrictive reimbursement practices.
  • Our ability to generate revenue will be diminished if our partners are unable to manage customer product substitutions for our prescription products.
  • Our inability to raise additional capital on acceptable terms in the future may cause us to curtail certain operational activities, including regulatory trials, sales and marketing, and international operations, in order to reduce costs and sustain the business, and such inability would have a material adverse effect on our business and financial condition.
  • Our information technology and infrastructure may be breached or attacked, which could expose us to liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business.
  • Our cash and cash equivalents may be exposed to failure of our banking institutions.
  • Risks Related to Our Common Stock
  • The market price of our common stock may be volatile, and the value of your investment could decline significantly.
  • Our operating results may fluctuate, which could cause our stock price to decrease.
  • Anti-takeover provisions in our certificate of incorporation and bylaws and under Delaware law may make it more difficult for stockholders to change our management and may also make a takeover difficult.
  • Our stockholders may experience substantial dilution in the value of their investment if we issue additional shares of our capital stock or other securities convertible into common stock.
  • Shares issuable upon the exercise of outstanding options may substantially increase the number of shares available for sale in the public market and depress the price of our common stock.
  • Our failure to maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of our common stock.

Legal proceedings

We may be involved in legal matters arising in the ordinary course of our business including matters involving proprietary technology. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may have a material adverse effect on our business, financial condition or results of comprehensive (loss) income.

The opening of Item 3, Legal Proceedings.6

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Yahoo FinanceSNOA quote
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
  50. 50
  51. 51
    SEC EDGAROther events
  52. 52
  53. 53
  54. 54
  55. 55
    SEC EDGAROther events
  56. 56
  57. 57